Trial
NCT00996892
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Solid Tumors
Intervention
Cobimetinib
Why stopped
A recommended Phase 2 dose and schedule was not identified and the study was terminated before initiation of Stage 2B.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-30